Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation and Depletion (2016)

Historic Depreciation and Depletion for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Q3 2016 value amounting to $248000.0.

  • Lineage Cell Therapeutics' Depreciation and Depletion fell 606.06% to $248000.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $1.3 million, marking a year-over-year increase of 2565.34%. This contributed to the annual value of $1.1 million for FY2015, which is 256.9% up from last year.
  • According to the latest figures from Q3 2016, Lineage Cell Therapeutics' Depreciation and Depletion is $248000.0, which was down 606.06% from $319000.0 recorded in Q2 2016.
  • In the past 5 years, Lineage Cell Therapeutics' Depreciation and Depletion registered a high of $429000.0 during Q1 2016, and its lowest value of $88692.0 during Q1 2012.
  • Moreover, its 5-year median value for Depreciation and Depletion was $249000.0 (2015), whereas its average is $217650.4.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first plummeted by 2474.87% in 2012, then skyrocketed by 13470.75% in 2014.
  • Over the past 5 years, Lineage Cell Therapeutics' Depreciation and Depletion (Quarter) stood at $102820.0 in 2012, then surged by 130.86% to $237370.0 in 2013, then rose by 8.27% to $257000.0 in 2014, then grew by 17.51% to $302000.0 in 2015, then decreased by 17.88% to $248000.0 in 2016.
  • Its last three reported values are $248000.0 in Q3 2016, $319000.0 for Q2 2016, and $429000.0 during Q1 2016.